Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 0.48 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | FNTA | P49354 | 2/20 | 0.30 |
| ▸ | FNTB | P49356 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17440237 | 1.00 | HSD11B1 (0.48) | HSD11B1DPP4CTSSCTSKJAK2 | |
| SCHEMBL17440255 | 0.86 | HSD11B1 (0.47) | HSD11B1DPP4CTSSCTSK | |
| SCHEMBL17440259 | 0.86 | HSD11B1 (0.47) | HSD11B1DPP4CTSSCTSK | |
| SCHEMBL705608 | 0.80 | KDM5A (0.32) | HSD11B1 | |
| SCHEMBL705607 | 0.80 | KDM5A (0.32) | HSD11B1 | |
| SCHEMBL527479 | 0.79 | DPP4 (0.30) | DPP4 | |
| SCHEMBL2167294 | 0.79 | KDM5A (0.31) | HSD11B1 | |
| SCHEMBL4877014 | 0.79 | HSD11B1 (0.33) | HSD11B1 | |
| SCHEMBL16337286 | 0.79 | HSD11B1 (0.33) | HSD11B1 | |
| SCHEMBL2167298 | 0.79 | KDM5A (0.31) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160015695-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015695-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | HSD11B1 4376/4885DPP4 857/4885CTSS 3142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.